Associate Professor, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed University), Porur, Tamil Nadu, India.
Professor and Head, Department of Biochemistry, St. Peter's Institute of Higher Education and Research, Avadi, Tamil Nadu, India.
Indian J Pharmacol. 2022 Mar-Apr;54(2):126-130. doi: 10.4103/ijp.ijp_47_20.
Embelin has been reported to possess variety of pharmacological activities such as androgenic antagonists, antiangiogenic, antibacterial, anticancer, anticonvulsant, antidiabetic, antidepressant, antihelmintic, antifertility, antihyperlipidemic, anti-inflammatory, antimalarial, antimitotic, antiobesity and antioxidant properties. The current research work aimed to study the hypoglycemic effect of embelin-chitosan nanoparticles (ECNPs) diabetic rats provoked by streptozotocin (STZ). Embelin nanoparticles (ENPs) were created by combining chitosan, a natural biopolymer, and glutaric acid, a new cross-linker. STZ 50 mg/kg was given intravenously into Sprague-Dawley rats weighing 250-300 g (75-90 days) to induce experimental diabetes. The antidiabetic efficacy of orally administered ECNPs in diabetic rats developed by STZ was investigated, as well as histological examination. When compared to diabetic control rats, ECNPs (25 mg/kg body weight and 50 mg kg body weight) and standard glibenclamide (10 mg/kg body weight) treated rodents exhibited a remarkable drop in glucose contents. Furthermore, histological research showed that ECNPs-treated rats were harmless up to amount of 25 mg/kg bwt. Thus current investigation reveals that ECNPs have antidiabetic potential and may be beneficial in treating hyperglycemia in people.
棓丙酯已被报道具有多种药理活性，如雄激素拮抗剂、抗血管生成、抗菌、抗癌、抗惊厥、抗糖尿病、抗抑郁、抗蠕虫、抗生育、抗高脂血症、抗炎、抗疟、抗有丝分裂、抗肥胖和抗氧化特性。本研究旨在研究棓丙酯-壳聚糖纳米粒（ECNPs）对链脲佐菌素（STZ）诱导的糖尿病大鼠的降血糖作用。通过将壳聚糖（一种天然生物聚合物）和戊二酸（一种新的交联剂）结合，制备出棓丙酯纳米粒（ENPs）。将 50mg/kg 的 STZ 静脉注射到 250-300g（75-90 天）重的 Sprague-Dawley 大鼠体内，诱导实验性糖尿病。研究了经 STZ 诱导的糖尿病大鼠口服 ECNPs 的降血糖效果，并进行了组织学检查。与糖尿病对照组大鼠相比，ECNPs（25mg/kg 体重和 50mg/kg 体重）和标准格列本脲（10mg/kg 体重）治疗的啮齿动物的血糖含量显著下降。此外，组织学研究表明，ECNPs 治疗的大鼠在 25mg/kg bwt 剂量下是无害的。因此，目前的研究表明，ECNPs 具有降血糖潜力，可能有益于治疗人类的高血糖。
